The global pharmacogenomics services market was valued at USD 6.35 billion in 2025 and is projected to grow from USD 6.71 billion in 2026 to USD 10.41 billion by 2034, registering a CAGR of 5.65% during the forecast period (2026–2034). The market is witnessing significant growth due to the increasing adoption of precision medicine, rising prevalence of chronic diseases, advancements in genomic sequencing technologies, and expanding applications of pharmacogenomics in drug development and personalized treatment strategies.

Key Highlights

• Market Size (2025): USD 6.35 Billion
• Market Size (2026): USD 6.71 Billion
• Forecast Market Size (2034): USD 10.41 Billion
• CAGR (2026–2034): 5.65%
• Base Year: 2025
• Forecast Period: 2026–2034
• Largest Region: North America
• Fastest Growing Region: Asia-Pacific (CAGR of 6.52%)
• Largest Segment by Service: Genotyping Services
• Fastest Growing Segment by Service: Whole Genome Sequencing Services (CAGR of 6.74%)
• Largest Segment by End User: Pharmaceutical & Biotechnology Companies
• Fastest Growing Segment by End User: Hospitals & Diagnostic Laboratories (CAGR of 6.83%)

Market Dynamics

Driver

The growing emphasis on personalized medicine and precision healthcare is a primary factor driving the pharmacogenomics services market. Healthcare providers are increasingly utilizing pharmacogenomic testing to identify genetic variations that influence individual responses to medications, enabling more effective treatment decisions while minimizing adverse drug reactions. In addition, technological advancements in next-generation sequencing (NGS), bioinformatics, and molecular diagnostics have significantly improved the accessibility, speed, and accuracy of pharmacogenomic testing, encouraging wider adoption across clinical and research settings.

Furthermore, increasing investments in genomic research, rising healthcare expenditure, and growing collaborations between pharmaceutical companies and genomic service providers are accelerating the integration of pharmacogenomics into drug discovery and development. Regulatory support for companion diagnostics and precision therapeutics is also contributing to market expansion.

Restraint

Despite promising growth prospects, the market faces challenges associated with the high cost of pharmacogenomic testing and limited reimbursement policies in several countries. The complexity of interpreting genomic data, shortage of skilled professionals, and lack of standardized clinical guidelines continue to hinder the widespread implementation of pharmacogenomics in routine healthcare practice.

Additionally, concerns related to genetic data privacy, ethical considerations, and varying regulatory frameworks across different regions may limit market penetration, particularly in developing economies where genomic infrastructure remains underdeveloped.

Opportunity

The increasing adoption of artificial intelligence (AI) and machine learning in genomic data analysis presents substantial growth opportunities for the pharmacogenomics services market. AI-powered platforms can accelerate the interpretation of complex genomic datasets, improve clinical decision-making, and facilitate the discovery of novel biomarkers for targeted therapies.

Moreover, expanding applications of pharmacogenomics in oncology, cardiovascular diseases, neurology, infectious diseases, and rare genetic disorders are expected to create significant business opportunities. Growing government initiatives supporting genomic medicine, expanding precision healthcare programs, and increasing awareness regarding individualized therapies are anticipated to further strengthen long-term market growth.

Top Market Players

• Thermo Fisher Scientific Inc.
• Illumina Inc.
• F. Hoffmann-La Roche Ltd.
• QIAGEN N.V.
• Laboratory Corporation of America Holdings (Labcorp)
• Eurofins Scientific
• Agilent Technologies Inc.
• Myriad Genetics Inc.
• BGI Genomics
• Exact Sciences Corporation

Market Segmentation

By Service

• Genotyping Services
• Whole Genome Sequencing Services
• Targeted Sequencing Services
• Gene Expression Profiling
• Others

By Application

• Oncology
• Cardiovascular Diseases
• Neurology
• Infectious Diseases
• Others

By End User

• Pharmaceutical & Biotechnology Companies
• Hospitals & Diagnostic Laboratories
• Academic & Research Institutes
• Contract Research Organizations (CROs)

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

Unlock Full Report Insights and Strategic Analysis: https://straitsresearch.com/report/pharmacogenomics-services-market

Unlock comprehensive insights into the global pharmacogenomics services market with Straits Research's in-depth report covering market trends, growth drivers, competitive landscape, regional analysis, emerging technologies, strategic opportunities, and future industry outlook to support informed business decisions.

About Us

Straits Research is a leading market research and market intelligence organization, specializing in research, analytics, and advisory services along with providing business insights and market research reports across diverse industries. Our research solutions help organizations identify emerging opportunities, evaluate market dynamics, and develop effective growth strategies.

Contact Us

Email: sales@straitsresearch.com

Tel:
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)